A61K31/095

THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS
20230172885 · 2023-06-08 ·

Provided herein, inter alia, are methods and compositions including thiol-containing compounds for treating coronavirus infection.

BISMUTH-THIOL COMPOSITIONS AND METHODS OF USE
20230165808 · 2023-06-01 ·

The invention relates to Bis-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating, managing or lessening the severity of pulmonary infections in a subject, the method comprising administering to the subject a bismuth-thiol (BT) composition that comprises at least one BT compound.

BISMUTH-THIOL COMPOSITIONS AND METHODS OF USE
20230165808 · 2023-06-01 ·

The invention relates to Bis-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating, managing or lessening the severity of pulmonary infections in a subject, the method comprising administering to the subject a bismuth-thiol (BT) composition that comprises at least one BT compound.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
20170333395 · 2017-11-23 ·

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
20170333395 · 2017-11-23 ·

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Tethering cysteine residues using cyclic disulfides
11254923 · 2022-02-22 · ·

Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including SOD1 and DJ-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization.

Tethering cysteine residues using cyclic disulfides
11254923 · 2022-02-22 · ·

Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including SOD1 and DJ-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization.

METHODS FOR DELIVERING AN ANTI-CANCER AGENT TO A TUMOR

Described herein are methods for delivering an anti-cancer agent to a tumor in a subject. The method involves administering to the subject (i) gold particles and (ii) at least one-anti-cancer agent directly or indirectly bonded to the macromolecule and/or unbound to the macromolecule; and exposing the tumor to light for a sufficient time and wavelength in order for the gold particles to achieve surface plasmon resonance and heating the tumor.

METHODS FOR DELIVERING AN ANTI-CANCER AGENT TO A TUMOR

Described herein are methods for delivering an anti-cancer agent to a tumor in a subject. The method involves administering to the subject (i) gold particles and (ii) at least one-anti-cancer agent directly or indirectly bonded to the macromolecule and/or unbound to the macromolecule; and exposing the tumor to light for a sufficient time and wavelength in order for the gold particles to achieve surface plasmon resonance and heating the tumor.

A METHOD FOR SIDE EFFECT REDUCTION IN THE USE OF STATINS VIA PHYSIOLOGICALLY SYNTHESIZED GLUTATHIONE
20170281713 · 2017-10-05 ·

Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of subjects suffering from diseases associated with hyperiipidemia and/or hypercholesterolemia. Related embodiments of the present invention relate to treatment and/or reducing the incidence of the side effects of statin therapy comprising administering to a subject in need, a composition comprising a glutathione precursor and a selenium source. Embodiments of the invention also relate to the use of the compositions in combination therapy with other agents such as statins, cholesterol absorption inhibitors, bile acid binding resins, or fibrates. In other embodiments, the invention relates to the use of such compositions comprising the glutathione precursor and the selenium source in the therapy of subjects suffering from erectile dysfunction and/or viral diseases such as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF).